Background
==========

In 1995 our institution developed a protocol to treat children with pamidronate. Several protocols have been published to treat osteogenesis imperfecta (OI) in the last decades. Objectives: to review the usefulness of our protocol in OI and to compare it with published protocols.

Materials and methods
=====================

Retrospective review of OI patients treated with pamidronate from 1995 to 2006 in our centre. Inclusion criteria: OI \< 18 years with z-score \< -2.5, fractures and z \< -1 or documented bone pain with z \< -1. Treatment: 60 mg or 30 mg (in prepubescents) of pamidronate every six months in a single dose.

Results
=======

20 patients included, average length of treatment 4.1 years (range: 18 months -- 8 years). Average Z-score increased from -4.3 to -2.9 after treatment and fracture rate decreased. Table [1](#T1){ref-type="table"} shows the comparison between our protocol and the ones published by Glorieux \[[@B1]\] and Arikoski \[[@B2]\].

###### 

Comparison between our protocol and the ones published by Glorieux and Arikoski

                                         HSJD                    Glorieux \[[@B1]\]   Arikoski \[[@B2]\]
  -------------------------------------- ----------------------- -------------------- --------------------
  Patients                               20                      30                   12
  Dose (mg/Kg/year)                      2.4(0.3)                6.8(1.1)             12
  Periodicity of infusions (m)           6                       3--4                 3
  Basal z-score                          -4.3(2)                 -5.3(1.2)            \*
  Final z-score                          -3.38(2.4) \*\*         -3.4(1.5)            \*
  Years of treatment                     3\*\*                   2.1(range 1.3--5)    1
  Mean annual increase in: z-score BMD   0.49 (0.1) 21.1 (5.1)   0.95 41.9 (29)       \* 63.5(37.3)

Mean(SD). m: months. \*Data not available. \*\* For comparability with the other series only the results of the first 3 years are shown.

Conclusion
==========

Despite a lower increase in z-score in our serie, the clinical efficacy is similar to other protocols. There is a tendency towards greater gain in Z-score as the annual dosage increases.
